Form 4: Tarsus CEO Transfers Shares to Family Trust
Insider Transaction Report
Tarsus Pharmaceuticals CEO Bobak R. Azamian transferred 51,885 shares of common stock to his living trust for no consideration, maintaining beneficial control.
Summary
- Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc., reported a change in beneficial ownership.
- On December 4, 2025, Azamian transferred 51,885 shares of Tarsus common stock to the Bobak Azamian Living Trust.
- The transfer was made for no consideration, indicating a gift or intra-family transfer.
- Following the transaction, Azamian directly owns 1,750 shares and indirectly owns 863,991 shares through the trust.
- Azamian remains the trustee of the Bobak Azamian Living Trust, established April 16, 2018, and retains voting and dispositive power over the transferred shares.
Sentiment
Score: 5
Explanation: Neutral. This is a routine insider transaction for estate planning purposes, with no direct operational or financial impact on the company or its stock price. The insider retains control over the shares.
Future Outlook
NA
Industry Context
This filing details a routine insider transaction for estate planning purposes and does not provide information related to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Beneficial Ownership Structure | Transfer of 51,885 common shares from direct ownership to indirect ownership via the Bobak Azamian Living Trust. The reporting person retains voting and dispositive power. | 12/04/2025 | No material change to corporate governance as the CEO retains control over the shares, but it formalizes an estate planning arrangement. |
Stakeholder Impact
- No direct impact on shareholders, employees, customers, suppliers, or creditors as this is an internal estate planning transaction by the CEO, with no change in overall beneficial control or company operations.
Key Dates
| Date | Description |
|---|---|
| April 16, 2018 | Bobak Azamian Living Trust established. |
| 12/04/2025 | Date of common stock transfer to Bobak Azamian Living Trust. |
| 12/08/2025 | Date of filing and signature by Attorney-in-Fact. |
Keywords
Tarsus Pharmaceuticals, TARS, Bobak Azamian, SEC Form 4, Beneficial Ownership, Stock Transfer, Living Trust, Insider Transaction, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.